Key Drivers
- Margin Expansion
- Cash Conversion
- Debt Reduction
AIAI Summary
JAZZ now looks less like a turnaround and more like a cash-generating specialty pharma compounder, with 15%+ revenue growth, ~88%–90% gross margins and ~$398M quarterly free cash flow supporting expansion, but it remains a prove-it story because the Zepzelca miss, acquisition-heavy strategy and still-levered balance sheet mean upside now depends on clean execution and successful new launches.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Margin Expansion
- •Cash Conversion
- •Debt Reduction
JAZZ swung from a 2025 loss to a profitable, cash-generative quarter in 2026 with strong margins and improving leverage, but elevated debt and an intangible-heavy balance sheet still make sustained earnings recovery the key risk.
Price Behavior
Key Price Behavior Insights:
- •Momentum fade
- •Support hold
- •Overhead resistance
Over the last month, JAZZ has faded from a strong rally into a cautious pullback, slipping from $261.62 to $244.96 and leaving it vulnerable unless it holds $243-$245 and reclaims $250-$256.
Failed rally from $261.62 to $244.96 after the early-August peak
Sentiment & News
Key News Insights:
- •Revenue beat
- •Pipeline expansion
- •Guidance raised
Jazz delivered record Q2 sales, raised 2026 guidance, and expanded its neuroscience pipeline with the Actio Biosciences acquisition, even as an EPS miss kept the quarter mixed. #M&A
The sales momentum and strategic M&A are likely supportive for the stock, but profitability execution remains a key watch point
Similar Companies in Healthcare
Other companies in the same sector with AI ratings